BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23494176)

  • 41. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
    Li M; Liu CL; Wang XY; Xue XM; Gao ZF
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
    Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.
    Kojima M; Nishikii H; Takizawa J; Aoki S; Noguchi M; Chiba S; Ando K; Nakamura N
    Leuk Lymphoma; 2013 Oct; 54(10):2149-54. PubMed ID: 23363269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children's Oncology Group.
    Smock KJ; Nelson M; Tripp SR; Sanger WG; Abromowitch M; Cairo MS; Perkins SL;
    Pediatr Blood Cancer; 2008 Oct; 51(4):489-94. PubMed ID: 18618503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Value of CD, MPO, Ki-67 and C-MYC Positive Rate in the Pathological Tissues and C-MYC Gene of Patients with T-LBL/ALL for Predicting Prognosis].
    Wu Y; Tang HY; Ding YY; Pan XQ; Tan CM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):110-115. PubMed ID: 29397827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
    Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
    [No Abstract]   [Full Text] [Related]  

  • 51. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
    Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
    Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Johnson NA; Slack GW; Savage KJ; Connors JM; Ben-Neriah S; Rogic S; Scott DW; Tan KL; Steidl C; Sehn LH; Chan WC; Iqbal J; Meyer PN; Lenz G; Wright G; Rimsza LM; Valentino C; Brunhoeber P; Grogan TM; Braziel RM; Cook JR; Tubbs RR; Weisenburger DD; Campo E; Rosenwald A; Ott G; Delabie J; Holcroft C; Jaffe ES; Staudt LM; Gascoyne RD
    J Clin Oncol; 2012 Oct; 30(28):3452-9. PubMed ID: 22851565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinicopathological features of primary cardiac CD5-positive and bcl-2 and C-MYC double expression diffuse large B-cell lymphoma].
    Zhang F; Luo DL; Chen Y; Liu J; Luo LQ; He J; Yan JH; Xu J; Luo XL; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Dec; 48(12):951-954. PubMed ID: 31818069
    [No Abstract]   [Full Text] [Related]  

  • 56. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
    Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
    Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
    Tapia G; Baptista MJ; Muñoz-Marmol AM; Gaafar A; Puente-Pomposo M; Garcia O; Marginet-Flinch R; Sanz C; Navarro JT; Sancho JM; Ribera JM; Ariza A; Mate JL
    APMIS; 2015 Jul; 123(7):596-603. PubMed ID: 26010683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Hermine O; Haioun C; Lepage E; d'Agay MF; Briere J; Lavignac C; Fillet G; Salles G; Marolleau JP; Diebold J; Reyas F; Gaulard P
    Blood; 1996 Jan; 87(1):265-72. PubMed ID: 8547651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinicopathological and genetic characteristics of diffuse large B-cell lymphoma of the oropharyngeal and maxillofacial region.
    Xia S; Yue J; Chen X; Hu Y; Guo F; Zhang J
    Oral Dis; 2021 Apr; 27(3):448-456. PubMed ID: 32731312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.